ClinicalTrials.gg
CompletedNCT03355651Updated Nov 30, 2017

Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction

An interventional study of PROGEN in ACL Reconstruction, sponsored by OPKO Health, Inc.. Completed. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-11-30.

Sponsored by OPKO Health, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Mar 2015, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This was a prospective, multicenter, randomized, open-label, phase IV trial to compare the efficacy of supplementation with plasma proteins, hydrolyzed collagen (CH), a complex of HA-CS (HC-15), and vitamin C combined with a standard rehabilitation protocol versus the standard rehabilitation protocol only after arthroscopically-assisted functional ACL reconstruction with hamstrings.

02

Conditions studied

  • ACL Reconstruction

Keywords

  • Anterior Cruciate Ligament Tears
  • Dietary Supplementations
  • Plasma Rich Proteins
  • Collagen
  • Chondroitin Sulfate
  • Hyaluronic Acid
03

In context

Anterior Cruciate Ligament Injuries

626 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.

This study's enrollment of 80 is above the median of 56 across 459 interventional studies indexed under Anterior Cruciate Ligament Injuries.

Browse Anterior Cruciate Ligament Injuries studies →

Lead sponsor

OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged between 18 and 55 years with partial or complete anterior cruciate ligament (ACL) rupture, diagnosed clinically and by Magnetic Resonance Imaging (MRI), requiring reconstructive surgery.
  • Patients with symptoms of acute or subacute ACL rupture (such as inflammation of the knee and pain with leg movement) or chronic ACL tear, including instability of the knee.
  • Patients with ACL ruptures without osteochondral lesions requiring additional surgery.
  • Patients with a medical history of therapeutic benefit using analgesic agents.

Exclusion criteria

Exclusion Criteria:

  • Patients with concomitant osteochondral pathology.
  • Patients treated with intra-articular injections of and/or -rich plasma, or with oral glucosamine, CS, HA or CH in the two months prior to surgery.
  • Patients with systemic diseases, those treated with antibiotics or other drugs that might alter the healing process, and those who had undergone arthroscopic lavage in the 90 days prior to surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    PROGEN Group

    PROGEN + Standard Rehabilitation + ACL reconstruction

    Dietary Supplement: PROGEN

  • No intervention
    Control Group

    Standard Rehabilitation + ACL reconstruction

Interventions

06

What researchers measure

Primary outcomes

  1. Pain improvement

    Assessed using a 100-mm Visual Analog Scale (VAS)

    Time frame: 90 days

Secondary outcomes

  1. Knee function

    Assessed using the International Knee Documentation Committee (IKDC) index. The final score was interpreted as a measure of function, with higher scores representing higher levels of function

    Time frame: 90 days

  2. Analgesic consumption

    Analgesic consumption and frequency of analgesic intake during follow-up

    Time frame: 90 days

  3. Number of rehabilitation sessions required

    Number of required rehabilitation sessions at the end of follow-up.

    Time frame: 90 days

  4. Maduration of the graft

    Assessed by MRI, by a single blind muskuloskeletal radiologist, using a standard procedure based on ACL oblique parasagittal T1 sequences

    Time frame: Day 0, day 90

Other outcomes

  1. Perceived efficacy and tolerability by both patients and physicians

    Perceived efficacy and tolerability were rated by both patients and physicians on a 5-point Likert scale, where higher scores indicated better efficacy and tolerability

    Time frame: 90 days

  2. Safety

    Assessed by means of all adverse events (AE) treatment related, reported at the end of follow-up.

    Time frame: 90 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Lopez-Vidriero E, Olive-Vilas R, Lopez-Capape D, Varela-Sende L, Lopez-Vidriero R, Til-Perez L. Efficacy and Tolerability of Progen, a Nutritional Supplement Based on Innovative Plasma Proteins, in ACL Reconstruction: A Multicenter Randomized Controlled Trial. Orthop J Sports Med. 2019 Feb 27;7(2):2325967119827237. doi: 10.1177/2325967119827237. eCollection 2019 Feb. PubMed 30834280 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Feb 2017, 22 months.

Of 287 interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2017
First posted
Nov 28, 2017
StartActual
Mar 9, 2015
Primary completionActual
Feb 1, 2017
CompletionActual
Mar 3, 2017
Last update
Nov 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03355651
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Nov 28, 2017
Start date
Mar 9, 2015
Primary completion
Feb 1, 2017
Completion
Mar 3, 2017
Last update
Nov 30, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Conjugated estrogens

Start the discussion